The transcription factor BACH2 promotes tumor immunosuppression

Journal of Clinical Investigation

Volumn 126, Issue 2, 2016, Pages 599-604

  Roychoudhuri, Rahul ^a,b   Eil, Robert L ^a   Clever, David ^a   Klebanoff, Christopher A ^a   Sukumar, Madhusudhanan ^a   Grant, Francis M ^b   Yu, Zhiya ^a   Mehta, Gautam ^a   Liu, Hui ^c   Jin, Ping ^c   Ji, Yun ^a   Palmer, Douglas C ^a   Pan, Jenny H ^a   Chichura, Anna ^a   Crompton, Joseph G ^a   Patel, Shashank J ^a   Stroncek, David ^c   Wang, Ena ^d   Marincola, Francesco M ^d   Okkenhaug, Klaus ^b   Gattinoni, Luca ^a   Restifo, Nicholas P ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b BABRAHAM INSTITUTE   (United Kingdom)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; GAMMA INTERFERON; RAG1 PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BACH2; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; BACH2 PROTEIN, MOUSE; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; ANIMAL; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; NEOPLASM; PATHOLOGY;

ADAPTIVE IMMUNITY; ANIMALS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; CD8-POSITIVE T-LYMPHOCYTES; IMMUNITY, INNATE; INTERFERON-GAMMA; MICE; MICE, KNOCKOUT; NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 84956901724     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI82884     Document Type: Review

References (25)

1. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253-268.
2. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6(4):295-307.
3. Quezada SA, Peggs KS, Simpson TR, Allison JP. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev. 2011;241(1):104-118.
4. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267-296.
5. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014-1022.
6. Muto A, et al. The transcriptional programme of antibody class switching involves the repressor Bach2. Nature. 2004;429(6991):566-571.
7. Muto A, et al. Bach2 represses plasma cell gene regulatory network in B cells to promote antibody class switch. EMBO J. 2010;29(23):4048-4061.
8. Roychoudhuri R, et al. BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature. 2013;498(7455):506-510.
9. Kim EH, Gasper DJ, Lee SH, Plisch EH, Svaren J, Suresh M. Bach2 regulates homeostasis of Foxp3+ regulatory T cells and protects against fatal lung disease in mice. J Immunol. 2014;192(3):985-995.
10. Nakamura A, et al. Transcription repressor Bach2 is required for pulmonary surfactant homeostasis and alveolar macrophage function. J Exp Med. 2013;210(11):2191-2204.
11. Sawcer S, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214-219.
12. Franke A, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010;42(12):1118-1125.
13. Cooper JD, et al. Meta-analysis of genomewide association study data identifies additional type 1 diabetes risk loci. Nat Genet. 2008;40(12):1399-1401.
14. Ferreira MA, et al. Identification of IL6R and chromosome 11q13.5 as risk loci for asthma. Lancet. 2011;378(9795):1006-1014.
15. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550.
16. Zhang N, Bevan MJ. CD8(+) T cells: foot soldiers of the immune system. Immunity. 2011;35(2):161-168.
17. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 2000;100(6):655-669.
18. Rutishauser RL, et al. Transcriptional repressor Blimp-1 promotes CD8(+) T cell terminal differentiation and represses the acquisition of central memory T cell properties. Immunity. 2009;31(2):296-308.
19. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. Cell. 1992;68(5):869-877.
20. Roychoudhuri R, Eil RL, Restifo NP. The interplay of effector and regulatory T cells in cancer. Curr Opin Immunol. 2015;33:101-111.
21. Vahedi G, et al. Super-enhancers delineate disease-associated regulatory nodes in T cells. Nature. 2015;520(7548):558-562.
22. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057-1061.
23. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. 2003;4(4):337-342.
24. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4(4):330-336.
25. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol. 2007;8(2):191-197.